Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups.
about
Solid-Phase Supports for Oligonucleotide SynthesisIntracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity.In vivo stability and kinetics of absorption and disposition of 3' phosphopropyl amine oligonucleotidesOligonucleotide inhibition of IL2R alpha mRNA transcription by promoter region collinear triplex formation in lymphocytesEffects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection.Modified deoxyoligonucleotides stable to exonuclease degradation in serum.shRNA and siRNA delivery to the brainComparison of several linear fluorophore- and quencher-conjugated oligomer duplexes for stability, fluorescence quenching, and kinetics in vitro and in vivo in miceGene delivery through the use of a hyaluronate-associated intracellularly degradable crosslinked polyethyleneimine.Radiolabeled oligonucleotides for antisense imaging.Synthesis and RNAse L binding and activation of a 2-5A-(5')-DNA-(3')-PNA chimera, a novel potential antisense molecule.Effects of RNA secondary structure on cellular antisense activity.Ex vivo regulation of specific gene expression by nanomolar concentration of double-stranded dumbbell oligonucleotides.4'-Thio-oligo-beta-D-ribonucleotides: synthesis of beta-4'-thio-oligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase.Inhibition of transcription by platinated triplex-forming oligonucleotides.The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity.Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cellsRNase H is responsible for the non-specific inhibition of in vitro translation by 2'-O-alkyl chimeric oligonucleotides: high affinity or selectivity, a dilemma to design antisense oligomers.Facile preparation of nuclease resistant 3' modified oligodeoxynucleotides.Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structuresDevelopment of antisense therapeutics. Implications for cancer gene therapy.Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras.Antisense strategy: biological utility and prospects in the treatment of hematological malignancies.Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy.Synthetic oligonucleotides as therapeutic agents.Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. An autoradiographic, immunohistological, and direct fluorescence microscopy study.Filtration-based perfusion of hybridoma cultures in protein-free medium: Reduction of membrane fouling by medium supplementation with DNase I.
P2860
Q29999315-3CD4D063-C044-4436-95AB-5DAFA59DFDFBQ31009736-B3D9927F-5DE1-4BA2-ACD2-A2BAF21CF21BQ35012323-ADE6667B-19ED-42F4-9500-B0A20E05BA51Q35768725-455A5DC7-7A95-4450-97AB-5FBB89AB7F6CQ35788817-BD8CAAB7-C80D-4004-A04A-6FD7077A48E9Q35913882-DB558D73-689A-4678-9F35-1F49364E9294Q36791813-E8482271-40B2-4E65-937C-DC48CD0F4DD2Q36909553-0E0E3025-FA49-4067-AD9D-065FBC46FFF4Q37393153-97DF9BBC-7A7D-4EBB-B508-F4123026C71FQ37913042-D656869D-B13F-4AC5-B59C-ADE75AEAFA8DQ38303875-8D8C3BCB-42D5-4E74-A750-18986A5079B7Q38315200-61C48C2F-FE7A-413E-B851-DB1707F10CBAQ38317483-1FA820B2-A6A7-4FCA-A21E-4800ED2C3367Q38320202-800A4B17-1E3E-4C30-939C-E1E596D79A7DQ38321890-0BFB20BA-0396-4D1D-83A5-6C9B1FB7AD39Q38344190-00DC9C12-CC21-42C7-9C60-9130A730A302Q40393427-E620E2B5-B306-4A83-A9C8-44B8876232BCQ40395644-D6F0821A-F165-4CBE-B8AB-34C203DCAB05Q40404618-EBE53E47-334E-416C-B277-51B0F1852CE5Q40420208-CFC1DF0F-A843-4584-A957-D697AE7D70CAQ40667901-831E7D6E-3A6F-42CB-B994-67D3A0E36D77Q41192006-8409AEF6-04A9-4D59-B650-C6271C5DF9D1Q41475501-64088DA8-ED2A-4DE7-B3BB-8A030ECED0E9Q42209643-2266DE15-AEEA-4CA9-B6A9-A7B89DCB0161Q42383801-EDC0AD79-47C6-486B-B382-21580FE93D5DQ42789464-E259A208-0FA5-4D9D-B578-5803E8569DA1Q47866541-630EFE0D-EA97-4E17-AF57-21E3E37A49A7
P2860
Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Partial protection of oncogene ...... inal methylphosphonate groups.
@en
type
label
Partial protection of oncogene ...... inal methylphosphonate groups.
@en
prefLabel
Partial protection of oncogene ...... inal methylphosphonate groups.
@en
P2860
P356
P1476
Partial protection of oncogene ...... inal methylphosphonate groups.
@en
P2093
H M Warenius
P2860
P2888
P304
P356
10.1038/BJC.1989.283
P407
P577
1989-09-01T00:00:00Z